Palexia Retard (Tapentadol Hydrochloride)

Tapentadol Hydrochloride, the active ingredient in Palexia Retard, is an opioid analgesic presented as a prolonged‑release formulation for oral use. It is indicated for the management of moderate to severe chronic pain in adult patients when alternative treatments are inadequate. GNH USA supplies Palexia Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Palexia Retard is an opioid analgesic that acts within the central nervous system to alleviate pain associated with several conditions. - Chronic low back pain: provides sustained relief of moderate to severe pain. - Osteoarthritis pain: improves functional ability by reducing pain intensity. - Neuropathic pain associated with diabetic peripheral neuropathy: lessens pain sensations and improves quality of life.

Adverse reactions to Palexia Retard can vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Constipation: reduced bowel movements. - Dizziness: sensation of light‑headedness. - Somnolence: increased sleepiness. - Headache: mild cranial pain. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that may be life‑threatening. - Seizures: convulsive episodes, particularly in patients with predisposition. - Severe hypotension: marked drop in blood pressure. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Dependence or abuse potential: risk of developing opioid use disorder. - adrenal insufficiency: rare hormonal imbalance affecting stress response.

When prescribing Palexia Retard, clinicians should consider several safety aspects. - Assess patient history: evaluate for prior opioid use, respiratory disorders, or substance abuse. - Monitor for sedation: watch   - Monitor      ");

--- ---   \n---